A no-deal Brexit – what next for the pharma industry?

13 March 2019

Even if the UK parliament votes against ‘no deal’ on Wednesday, in the wacky world of Brexit, this cliff-edge scenario is still possible – so Stevens & Bolton partner Charlotte Tillett (pictured above, left) and senior associate Paula Harris (right), consider the potential implications for pharma in an Expert View piece.

As Brexit approaches, the industry’s preparations for a potential no-deal scenario are well underway, but the impracticalities of preparing for the unknown are stark. There are, however, some key business critical points that pharmaceutical companies can consider in the run-up, which will stand them in good stead in the event of a no-deal Brexit.

What has the government said so far?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK